Press Releases
Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet® Animal Cancer Division. The company’s patented Precision Radionuclide Therapy™ (PRnT™) treated an unprecedented number of pets in Q1 2025, marking a 150% year-over-year increase in treatment volume. This milestone underscores IsoPet®’s growing role as a transformative, non-invasive solution for veterinary oncology.
Read the full press release here.
IsoPet® is our division dedicated to treating cancers in animals using our patented Precision Radionuclide Therapy™ (PRnT). Our innovative approach in the treatment of cancerous tumors focuses on delivering targeted radiation directly to cancerous tumors in a single treatment while minimizing damage to surrounding healthy tissues.
Deliver your active pharmaceutical with quick-dissolving, biodegradable thermogel consisting of poly(lactide-co-glycolide)-graft-poly(ethylene glycol). Initially developed at Pacific Northwest Laboratories and further refined by a collaboration between Vivos, Inc. and Akina, Inc.
RadioGel® is our division dedicated to treating cancer in humans using our patented Precision Radionuclide Therapy™ (PRnT). RadioGel® is currently not approved for human use or commercial distribution in the United States. It is being studied under an FDA-approved Investigational Device Exemption (IDE) for clinical trials only.